Correspondence 0001104659-25-026629 from ProQR Therapeutics N.V. (PRQR)
ProQR Therapeutics N.V.
Date: March 21, 2025 · CIK: 0001612940 · Accession: 0001104659-25-026629
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285767
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, DC 20549 Attention: Jessica Dickerson Re: ProQR Therapeutics N.V. Acceleration Request for Registration Statement on Form F-3 File No. 333-285767
Dear Jessica Dickerson:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), ProQR Therapeutics N.V. (the " Company ") hereby requests that the effective date and time of the above-referenced registration statement (the " Registration Statement ") be accelerated to March 25, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Adam V. Johnson at (212) 459-7072. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the " Commission ") verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Adam V. Johnson, by email to AdamJohnson@goodwinlaw.com.
If you have any questions regarding this request, please contact Adam V. Johnson of Goodwin Procter LLP at (212) 459-7072.
Sincerely,
pROQR
thERAPEUTICS N.V.
Show Raw Text
CORRESP 1 filename1.htm VIA EDGAR March 21, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Jessica Dickerson Re: ProQR Therapeutics N.V. Acceleration Request for Registration Statement on Form F-3 File No. 333-285767 Dear Jessica Dickerson: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), ProQR Therapeutics N.V. (the " Company ") hereby requests that the effective date and time of the above-referenced registration statement (the " Registration Statement ") be accelerated to March 25, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Adam V. Johnson at (212) 459-7072. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the " Commission ") verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Adam V. Johnson, by email to AdamJohnson@goodwinlaw.com. If you have any questions regarding this request, please contact Adam V. Johnson of Goodwin Procter LLP at (212) 459-7072. Sincerely, pROQR thERAPEUTICS N.V. /s/ René Beukema René Beukema Chief Corporate Development Officer and General Counsel cc: Jurriaan Dekkers, ProQR Therapeutics N.V. Mitchell S. Bloom, Goodwin Procter LLP Adam V. Johnson, Goodwin Procter LLP